ArticleInvestigative ophthalmology & visual science2012
Antibody-mediated retinal pericyte injury: implications for diabetic retinopathy.
Article in Investigative ophthalmology & visual science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Transcriptomic Characterization of Terminal Complement Complex-bound Cells in Human Choroid Using Single-Cell RNA Sequencing.bioRxiv : the preprint server for biology · 2026Article
- The Calcium Signalling Profile of the Inner Blood-Retinal Barrier in Diabetic Retinopathy.Cells · 2025Review
- Incidence of diabetic retinopathy in anti-tnf treated rheumatic disease patients with type 2 diabetes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- The innate immune system in diabetic retinopathy.Progress in retinal and eye research · 2021Review
- Qualitative and Quantitative Analysis of B-Cell-Produced Antibodies in Vitreous Humor of Type 2 Diabetic Patients with Diabetic Retinopathy.Journal of diabetes research · 2020Article
- Role of ω3 polyunsaturated fatty acids in diabetic retinopathy: a morphological and metabolically cross talk among blood retina barriers damage, autoimmunity and chronic inflammation.Lipids in health and disease · 2019Review
- Modulation of three key innate immune pathways for the most common retinal degenerative diseases.EMBO molecular medicine · 2018Review
- Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- DesigningFrontiers in aging neuroscience · 2018Article
- New insight into the role of the complement in the most common types of retinopathy-current literature review.International journal of ophthalmology · 2018Review
- Diabetes-related changes in the protein composition and the biomechanical properties of human retinal vascular basement membranes.PloS one · 2017Article
- Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients.Scientific reports · 2016Article
- Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.Clinical and experimental immunology · 2016Review
- Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology.Journal of diabetes research · 2016Review
- Proteasome Activators, PA28International journal of nephrology · 2016Article
- Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose.PloS one · 2016Article
- Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?Omics : a journal of integrative biology · 2015Review
- From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathy.Current diabetes reports · 2015Review
- Future Vision 2020 and Beyond-5 Critical Trends in Eye Research.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Review
- Diabetes and retinal vascular dysfunction.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo test the hypothesis that autoantibodies against retinal pericytes could develop in diabetic retinopathy, and that these autoantibodies could induce retinal pericyte dysfunction/death via complement.
methodsHuman primary retinal pericytes cultured in media containing normal (5 mM) or high (30 mM) glucose concentrations were incubated with normal human sera in the presence of a retinal pericyte-reactive antibody, then their viability was assessed by a BCECF-based cytotoxicity assay, and their function was assessed by a T-cell proliferation assay. The pericytes were also analyzed by RT-PCR and flow cytometry to detect CD38, an established diabetes-associated cell surface autoantigen. The potential of the anti-CD38 antibodies in inducing pericyte cellular injury was evaluated using the same cytotoxicity assays. In addition, autoantibody-mediated cytotoxicity in mouse retinal pericytes sensitized by sera from mice with developing diabetic retinopathy or control normal mice were also studied.
resultsRetinal pericyte-reactive antibodies induced cellular damage by activating complement in the serum. The antibody-injured pericytes had reduced efficacy in inhibiting T cells. Hyperglycemic culture conditions rendered pericytes more susceptible to antibody-mediated attack. CD38 was expressed in retinal pericytes, and upregulated by TNF-α and IFN-γ, and anti-CD38 antibodies induced pericyte cytotoxicity. Retinal pericytes sensitized with sera from chronic diabetic mice suffered significantly augmented cytotoxicity compared with those sensitized with sera from the control mice.
conclusionsThe autoantibody-initiated complement activation could be a mechanism underlying the loss of function, and eventually, death of retinal pericytes in diabetic patients, suggesting that inhibiting complement activation could be a novel therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.